Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verdiperstat - Biohaven Pharmaceutical Holding Company

Drug Profile

Verdiperstat - Biohaven Pharmaceutical Holding Company

Alternative Names: AZD 3241; BHV3241

Latest Information Update: 25 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biohaven Pharmaceutical Holding Company
  • Class Antiparkinsonians; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy
  • Discontinued Parkinson's disease

Most Recent Events

  • 23 Jan 2019 The USFDA accepts IND application to initated clinical investigation of Verdiperstat for Multiple system atrophy
  • 03 Dec 2018 Chemical structure information added
  • 14 Nov 2018 Biohaven Pharmaceuicals plans a phase III trial of verdiperstat for Multiple System Atrophy (MSA) in the third quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top